58238
document
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma : correlative analysis from a large North American cooperative group trial . Epstein-Barr virus ( EBV ) is associated with Hodgkin lymphoma ( HL ) and can be detected by in situ hybridization ( ISH ) of viral nucleic acid ( EBER ) in tumor cells . We sought to determine whether plasma EBV-DNA could serve as a surrogate for EBER-ISH and to explore its prognostic utility in HL . Specimens from the Cancer Cooperative Intergroup Trial E2496 were used to compare pretreatment plasma EBV-DNA quantification with EBV tumor status by EBER-ISH . A cutoff of > 60 viral copies/100 µL plasma yielded 96 % concordance with EBER-ISH . Pretreatment and month 6 plasma specimens were designated EBV ( - ) or EBV ( + ) by this cutoff . Patients with pretreatment EBV ( + ) plasma ( n = 54 ) had inferior failure-free survival ( FFS ) compared with those with pretreatment EBV ( - ) plasma ( n = 274 ) , log-rank P = .009 . By contrast , no difference in FFS was observed when patients were stratified by EBER-ISH . Pretreatment plasma EBV positivity was an independent predictor of treatment failure on multivariate analyses . At month 6 , plasma EBV ( + ) patients ( n = 7 ) had inferior FFS compared with plasma EBV ( - ) patients ( n = 125 ) , log-rank P = .007 . These results confirm that plasma EBV-DNA is highly concordant with EBER-ISH in HL and suggest that it may have prognostic utility both at baseline and after therapy . This trial was registered at www.clinicaltrials.gov as # NCT00003389 .
58239
Intervention_Physical
pretreatment plasma EBV-DNA quantification
58240
Intervention_Physical
EBV tumor status
58241
Intervention_Other
by
58242
Intervention_Physical
EBER-ISH
58243
Outcome_Physical
EBER-ISH
58244
Outcome_Physical
tumor status
58245
Outcome_Physical
EBER-ISH
58246
Participant_Condition
advanced Hodgkin lymphoma